Notify me when QVT Financial LP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ALLT | Allot Ltd. | Ordinary Shares, par value ILS 0.10 per share | 10% | $47,739,592 | +$14,208,464 | 5,062,523 | +42% | QVT Financial LP | 18 Nov 2025 |
| WHWK | Aadi Bioscience, Inc. | Common stock, $0.0001 par value per share | 9.4% | $3,817,608 | 2,313,702 | QVT Financial LP | 31 Dec 2024 | ||
| TRML | Tourmaline Bio, Inc. | Common Stock, $0.0001 par value per share | 8.4% | $49,686,298 | +$15,710,409 | 2,154,653 | +46% | QVT Financial LP | 30 Jun 2025 |
| ROIV | Roivant Sciences Ltd. | Common shares, par value $0.0000000341740141 per share | 4.3% | $351,404,355 | -$435,489,242 | 29,381,635 | -55% | QVT Financial LP | 30 Jun 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|